Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study
Bibliographic record
Abstract
Abstract Introduction Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy designed to decouple recombinant FVIII from endogenous von Willebrand factor. In the Phase 3 XTEND-1 (NCT04161495) and XTEND-Kids (NCT04759131) studies, once-weekly efanesoctocog alfa exhibited effective bleed protection, was well tolerated, providing FVIII activity within the normal to near-normal (>40%) range for 4 and 3 days, respectively, at steady state. We present the third interim analysis of the XTEND-ed (NCT04644575) long-term extension study examining the safety and efficacy of efanesoctocog alfa prophylaxis in patients with severe hemophilia A. Methods Participants who completed XTEND-1 (≥12 years) and XTEND-Kids (<12 years), could continue once-weekly 50 IU/kg efanesoctocog alfa prophylaxis in the ongoing, multicenter, open-label, long-term XTEND-ed study. The primary endpoint was the incidence of FVIII inhibitor development and secondary endpoints included annualized bleed rates (ABRs), efficacy for bleed treatment, and safety. Data cut: February 21, 2025. Results Among adults and adolescents, 146 participants rolled over from XTEND-1 to XTEND-ed baseline with a median (range) age of 37.0 (13.0–74.0) years. The median (range) treatment duration in XTEND-ed was 166.0 (14.1–192.7) weeks, comprising a median (range) of 167.0 (14.0–200.0) exposure days (EDs). The median (range) cumulative treatment duration from XTEND-1 baseline until XTEND-ed data cut was 212.2 (46.3–244.8) weeks, comprising a median (range) of 216.5 (47.0–254.0) EDs. No FVIII inhibitor development was observed. During XTEND-ed, the mean (SD) ABR for Day 1–Month 12 (n=146) was 0.70 (1.31), Months 12–24 (n=141) was 0.62 (1.23) and Months 24–36 (n=132) was 0.45 (1.24), with 96/146 (65.8%), 96/141 (68.1%), and 103/132 (78.0%) participants with zero bleeds, respectively. The mean (95% CI) model-based ABR for the efficacy period was 0.60 (0.47; 0.76) for overall treated bleeds, and 0.20 (0.15; 0.28) and 0.29 (0.22; 0.39) for spontaneous and traumatic bleeds, respectively. Of 252 treated bleeding episodes, 94.0% (237) were resolved with 1 efanesoctocog alfa injection; participants rated the response excellent/good for 87.8% (173/197) bleeds. The median (range) weekly efanesoctocog alfa consumption was 51.6 (39.4–58.9) IU/kg. In total, 126 participants (86.3%) experienced ≥1 treatment-emergent adverse event (TEAE), most commonly COVID-19 (26.7%), arthralgia (17.1%), influenza (15.1%), and nasopharyngitis (15.1%). Two participants had ≥1 treatment-related TEAE (facial paralysis and reduced FVIII levels); no treatment-related serious TEAEs were reported. TEAEs unrelated to study drug led to the death of 2 participants and treatment discontinuation in 3 participants. Among children, 71 participants (<6 years, n=35; 6–<12 years, n=36) rolled over from XTEND-Kids to XTEND-ed, with the median (range) treatment duration of 116.7 (36.3–152.6) weeks, comprising a median (range) of 116.0 (11.0–153.0) EDs. The median (range) cumulative treatment duration from XTEND-Kids baseline until XTEND-ed data cut was 169.8 (88.2–204.7) weeks, with a median (range) of 171.0 (65.0–207.0) EDs. No FVIII inhibitors were observed. During XTEND-ed, the mean (SD) ABR evaluated for Day 1–Month 12 (n=71) was 0.68 (1.13) and Months 12–24 (n=62) was 0.49 (0.82), with 46/71 (64.8%) and 41/62 (66.1%) participants with zero bleeds, respectively. The mean (95% CI) model-based ABR was 0.64 (0.48; 0.85) for overall treated bleeds, and 0.08 (0.04; 0.15) and 0.44 (0.31; 0.62) for spontaneous and traumatic bleeds, respectively. Of 89 treated bleeding episodes, 91.0% (81) were resolved with 1 efanesoctocog alfa injection; participants rated the response excellent/good for 94.1% (64/68) bleeds. The median (range) weekly efanesoctocog alfa consumption was 54.0 (46.2–73.1) IU/kg. Overall, 60 (84.5%) participants experienced ≥1 TEAE; most commonly pyrexia (18.3%), upper respiratory tract infection (16.9%), arthralgia (15.5%), and cough (15.5%). Two participants had ≥1 treatment-related TEAE (asthma and post infusion pain and headache); no treatment-related serious TEAEs or treatment discontinuations were reported. Conclusion Results from up to 4 years of the XTEND-ed study demonstrate that once-weekly efanesoctocog alfa continues to be well tolerated, providing highly effective bleed protection with no inhibitor development in adults, adolescents, and children with severe hemophilia A.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.003 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".